Delivering Superior Signal Clarity

On a mission to end reliance on mixed signals and reading between the lines, BioSig Technologies understands that greater clarity breeds opportunity for a new standard in cardiac care.

Learn More
Beyond the Status Quo

Beyond the Status Quo

As physician advocates, we develop technology that provides greater clarity and opens doors to ingenious treatment solutions for the most challenging arrhythmias. We collaborate with physicians, experts, and healthcare leaders to align on the advancements that can be realized in the field of electrophysiology.

We are driven by a commitment to provide innovative solutions that elevate the standard of care. Our engineers are constantly in search of what’s possible in signal acquisition and the field of electrophysiology, driving the evolution of our technology for the physicians we serve.

An Innovation in One of the Most Critical Areas of Electrophysiology

An Innovation in One of the Most Critical Areas of Electrophysiology

The PURE EP™ Platform applies a unique combination of hardware and software to accurately capture intracardiac signals with unprecedented clarity and precision. By viewing pure signals that are absent of saturation, interference, or noise from other medical equipment, physicians can respond to even the most complex cardiac arrhythmias with insight-based, highly targeted cardiac ablation procedures.

Discover the PURE EP™ Platform

MEETING THE NEED TO IMPROVE ARRHYTHMIA TREATMENT

Leveraging EGMs to Improve Efficacy, Safety of Ablation: A Physician’s Perspective

"If we improve the fidelity of our [signal] recordings, we can potentially improve the efficiency and safety of our procedures. In that respect, the PURE EP™ System is really a breath of fresh air in this field."

- Hicham El Masry, M.D. (Mayo Clinic, Arizona)
Leveraging EGMs to Improve Efficacy, Safety of Ablation Kansas City Heart Rhythm Symposium (KCHRS) 2022

Discover BioSig

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join Our Team

Company

BioSig is an advanced signal processing company delivering unmatched accuracy and precision to intracardiac signal visualization, and enhancing the treatment of arrhythmias.

Learn more about BioSig

Leadership

By uniting the diverse talents and collective experiences of industry experts, we are determined to break down barriers and go beyond our comfort zone in pursuit of unconventional solutions that advance medical technology and make a lasting impact.

Careers

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join our team

Insights

With the superior, real-time visualization of arrhythmias, PURE EP™ is paving the way for personalized patient care and breakthrough innovations in the field of electrophysiology. View the latest cases, presentations, and papers.

Explore physician insights

News & Stories

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer


Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or ('BioSig' or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.

BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules


Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ('BioSig' or the 'Company') a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants are immediately exercisable and will expire five years from the date of issuance.

BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules


Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ('BioSig' or the 'Company') a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, BioSig has also agreed to issue and sell to the same purchasers unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants will become immediately exercisable upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about May 30, 2024, subject to the satisfaction of customary closing conditions.